Sön 14 jul / År 42 / Nr 3 2024

Nordic CRO with Strong Presence in Öresund

The contract research organisation IRW Consulting sees a strong demand for clinical trial management, not least in Denmark and Southern Sweden, and plans for several new projects in Lund and Malmö in 2017 and 2018.

IRW Consulting is a premium, full-service, contract research organisation (CRO) that has worked with outsourced clinical research for over 17 years. The company has a strong Nordic presence with regional offices in Denmark, Finland, Norway and Sweden. Their experienced locally-based staff can assist their customers conducting clinical trials as per country specific laws and regulations.
”We cover all the stages of clinical development, from phase I to phase IV, including paediatric and non-interventional studies and medical device investigations. Our customers range from virtual biotech companies and medtech companies to big pharma and other CROs. Depending on the customer’s requirements, our staff is either outsourced or works with in-house projects,” says Ola Jeppsson, Vice President Nordic, IRW Consulting AB, headquartered in Stockholm.
The company has a strong presence in the Medicon Valley region with their second largest office located in Copenhagen. There’s a strong demand in Denmark and Southern Sweden and IRW Consulting plans for several new projects in Lund and Malmö in 2017 and 2018.

40% of Trials are in Oncology
”The number of projects is growing in a wide range of therapeutic areas, not least in oncology. Approx. 40% of the trials we manage are in oncology. We’re planning to recruit more people in 2017, especially in Denmark and Sweden, and are constantly in search of new highly skilled professionals experienced in conducting clinical trials,” Ola Jeppsson adds.
IRW Consulting is increasingly performing clinical trials outside the Nordic countries. Primarily in Germany, France, the UK and Poland, but also in the US and other non-European countries. After some years of decline in clinical trials, the Swedish market is witnessing an increase both in the number of companies and in the number of projects entering clinical development.
”The conditions for performing trials in Sweden are very good and many companies, both from Sweden and abroad, choose to conduct their studies here. With our engagement and extensive network of clinics we can overcome the bottlenecks regarding time and access to patients that sometimes occur. By showing this we’ve attracted companies from other parts of EU to expand their trials to Sweden as well,” says Ola Jeppsson.